PTO/SB/81 (01-06)

Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are

## **POWER OF ATTORNEY** and **CORRESPONDENCE ADDRESS INDICATION FORM**

Application Number	10/632,6455
Filing Date	8/1/2003
First Named Inventor	Couto, Linda B.
Title	Adeno-associated vector
Art Unit	1635
Examiner Name	Whiteman, Brian
Attorney Docket Number	1011.CON1.2

I hereby revok	e all previous powers of attorr	ney given in the above-identified application.	
n OR	ociated with the Customer Number:	24536	
☐ Practitioner(s) na			
	Name	Registration Number	
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.			
<del></del>	r change the correspondence address for	or the above-identified application to:	
The address associated with the above-mentioned Customer Number			
<i>OR</i> ☐ The address a	ssociated with Customer Number:		
OR	<u> </u>		
☐ Firm <i>or</i> Individual Name			
Address			
City		State ZIP	
Country			
Telephone		Email	
I am the:  Applicant/Inventor.  Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)			
SIGNATURE of Applicant or Assignee of Record			
Signature	Malshotan	Date 1/28/08	
Name	Elizabeth Lassen	Telephone (508) 270-2553	
Title and Company		nzyme Corporation	
NOTE: Signatures of all t more than one signature	he inventors or assignees of record of the enti	re interest or their representative(s) are required. Submit multiple forms if	
*Total of	forms are submitted.		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/96 (01-08) Approved for use through 01/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.  Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Genzyme Corporation
Application No./Patent No.: 10/632,645 Filed/Issue Date: 8/1/2003
Entitled Adeno-associated vector compositions for expression of factor VIII
Genzyme Corporation , a <u>Massachusetts Corporation</u> (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:  1. X the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)
in the patent application/patent identified above by virtue of either:
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
OR  B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: Inventor To: Avigen, Inc. The document was recorded in the United States Patent and Trademark Office at
The document was recorded in the United States Patent and Trademark Office at Reel <u>010390</u> , Frame <u>0989</u> , or for which a copy thereof is attached.
2. From: Avigen, Inc. To: Genzyme Corporation
The document was recorded in the United States Patent and Trademark Office at Reel $020010$ , Frame $0567$ , or for which a copy thereof is attached.
3. From: To: The document was recorded in the United States Patent and Trademark Office at
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.  [NOTE: A separate copy ( <i>i.e.</i> , a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee
Signature
Signature / Date (508) 270-2553
Printed or Typed Name Telephone Number
Managing IP Counsel, Genzyme Corporation
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Genzyme Corporation 500 Kendall Street Cambridge, MA 02142 T 617-252-7500

## SIGNATURE AUTHORITY

I, Thomas J. DesRosier, Senior Vice President and General Counsel of Genzyme Corporation hereby appoint Madge K. Shafmaster, Senior Vice President and Chief Patent Counsel; Bart G. Newland, Vice President, Intellectual Property; Richard Allison, Managing Intellectual Property Counsel; Elizabeth Lassen, Managing Intellectual Property Counsel; and Jennifer L. Dupré, Managing Intellectual Property Counsel, all of Genzyme Corporation, with full power and authority to transact any and all business before the United States Patent and Trademark Office, and any foreign counterpart patent office, with the powers of a Corporate Officer of Genzyme Corporation.

Date: January 24, 2008

Thomas J. DesRosier

Senior Vice President and General Counsel

**GENZYME CORPORATION**